- The FDA has signed off Iovance Biotherapeutics Inc's (NASDAQ:IOVA) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC).
- IOV-4001 leverages the gene-editing TALEN technology licensed from Cellectis SA (NASDAQ:CLLS).
- A clinical study of IOV-4001 in patients with metastatic melanoma or stage III or IV NSCLC is expected to begin in 2022.
- Read Next: Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers.
- A poster highlighting preclinical activity, clinical-scale manufacturing process development, and characterization of IOV-4001 will be presented at American Association for Cancer Research 2022 Annual Meeting.
- In the AACR abstract, the anti-tumor activity of IOV-4001 was superior to non-edited TIL and non-edited TIL in combination with anti-PD-1 in a murine model.
- Price Action: IOVA shares traded 5.92% higher at $13.25 during premarket trading on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks